Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
LEDiR: A Ground-breaking Manufacturing Process to Yield a Unique Prosthesis for Lumbar Endoscopic Disc Replacement (LEDiR)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Nanotechnologies
Action type: SME instrument
Countries involved: Italy
Call: Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs (H2020-SMEINST-1-2016-2017, 2017)
Start date: 2017-05-01
End date: 2017-08-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 2
Project status: CLOSED

Today our society faces a major challenge coming from the progressive ageing of the population & the rising incidence of chronic diseases. Indeed, the healthcare system is desperately seeking for new ways to address the many conditions arising due to the natural ageing process. One of these conditions is the group of degenerative disc diseases, which entails a deterioration of the vertebral discs responsible for the flexibility & cushioning of our spine. This condition affects around 40% of the population aged 40, increasing up to 80% when aged 60. Although there is some room for management if diagnosed early, most patients need to undergo surgery for replacement by either fixing the vertebrae or introducing a prosthesis. However, both the materials used for the replacements and the surgical procedures have important shortcomings in terms of safety, risks, costs, biocompatibility and spine recovery. Thus, there is a clear need to find an alternative that is less invasive and more cost-effective to the healthcare system. In response, the consortium made by Additiva & Tsunami aims to bring to market LEDiR, an innovative prosthesis for lumbar disc replacement whose fully articulated structure enables implantation through a non-invasive endoscopic approach. While a ground-breaking process of laser sinterization confers LEDiR a unique form that mimics the shape of the spine, a core of biocompatible silicon brings its flexibility. After proving the safety & reliability of the production process and the prosthesis, we now want to finalise its development and prepare LEDiR for the market stage. The Feasibility Study planned for Phase 1 aims to warrant our project from all technical, financial & commercial points of view. Upon completion of this project, we will be able to bring significant benefits to society in terms of life quality for patients & huge savings for the healthcare system. In turn, after 5 years we expect to obtain €10.6 million in revenues and a ROI of 5.25.

Keywords: orthopedic implants,disc replacement prosthesis,laser sinterization process,3d laser printing,tailored titanium plates,biocompatible silicon core
Contributing to identify causes of gender violence among teenagers (FREE_TEEN_DESIRE)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: United Kingdom
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Start date: 2015-08-17
End date: 2016-08-16
Duration (months): 12.0
Total project cost (EUR): 97727.4
EU funding (EUR): 97727.4
Participants: 1
Project status: CLOSED

The frequency of gender violence today is extremely high; 35% of women worldwide experienced either physical and/or sexual intimate partner violence or non-partner sexual violence (World Health Organization, 2013). In 2009, Miguel Carcaño, adolescent, confesses to have raped and killed his ex-girlfriend, Marta del Castillo. After entering prison, a platform started in support of the self-confessed murderer, through which his admirers declared their desire to meet and to start a relationship with him. While many studies are being conducted to understand and ameliorate this situation, further research is needed to better identify the causes and consequences and to analyze in-depth methods that can advance research on this topic. The applicant has worked for the last fourteen years on the fact that some adolescents have been socialized into a type of relationships that link attraction and violence. FREE_Teen_Desire will draw from this background and learn from host expertise and methodological approaches in order to: 1) explore the extent to which dialogue situations (based on a language of desire) can question adolescent girls’ desires that link attractiveness to violent behaviours, 2) assess whether this dialogic questioning of girls’ desire, if any, is true beyond cultures, thus breaking down cultural and racist stereotypes associated to violence against women, and 3) develop the evidence-based approaches needed to increase effectiveness in the prevention of gender violence among adolescents. The research will have a mixed methods approach, involving a quasi-experimental study with 240 adolescent girls from four different countries and a qualitative analysis of some of their stories. The project will also innovate in dissemination and outreach activities in order to achieve political and social impact, in prevention campaigns and programmes against gender based violence.

Keywords: gender violence,desire,teenagers,criminology
Novel insights into DNA damage and stress responses in the nucleolus: Mechanisms and relevance for genomic (in)stability and cancer (rDNAstress)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Denmark
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2019-01-01
End date: 2020-12-31
Duration (months): 24.0
Total project cost (EUR): 212194.8
EU funding (EUR): 212194.8
Participants: 1
Project status: CLOSED

Incidence of grave pathologies including neurodegeneration and cancer increases in today’s aging European populations and new approaches to battle these diseases are required. Shared by these pathologies and premature aging syndromes is the enhanced DNA damage and genomic instability, likely causal phenomena that can be better understood by functional elucidation of the cellular DNA damage response (DDR) machinery and its defects. The central hypothesis of this project is that ‘nucleolar genome’ that contains many copies of rDNA genes, the repetitive and most highly transcribed genomic sequences essential for ribosome biogenesis and protein synthesis, may represent an exceptionally vulnerable ‘Achilles heel’ of our genome whose instability fuels aging and tumorigenesis. This project proposes to approach this problem by a combination of innovative cellular models and techniques including gene editing, proteomics and live cell imaging, to assess rDNA damage and the ensuing genomic instability in human cells exposed to exogenous (radiation, chemotherapy drugs) and endogenous (replication and transcription stress, ribosome biogenesis stress, activated oncogenes) insults and identify and functionally characterize signalling and ‘repair’ factors that guard nucleolar integrity and function. This proposal is timely due to the emerging concept of nucleolus as a sensor of diverse stresses and the fact that technological advances now allow analysis of the difficult-to-assess rDNA genes. The applicant is experienced in the DDR field and modern technologies, the receiving institute is among the world leading centers in DNA damage, cancer and cell stress research fields. These aspects, together with the large body of preliminary unpublished data makes this ambitious project feasible. The results will provide novel insights into genome integrity maintenance and cell stress responses, and may inspire novel strategies to treat or even prevent age-related diseases, especially cancer.

Keywords: dna repair,ribosomal dna,nucleolus,homologous recombination,cancer,aging,stress response,dna damage,oncogenes
Rational Design for Coke-resistant Dry Reforming Catalyst using Combined Theory and Operando Raman Experiments (Biogas2Syngas)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Italy
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2019-11-01
End date: 2021-10-31
Duration (months): 24.0
Total project cost (EUR): 171473.28
EU funding (EUR): 171473.28
Participants: 1
Project status: CLOSED

Increasing energy & chemical demands, rising CO2 emission and depleting fossil reserves have necessitated a search for an alternative technology to mitigate environmental issues, reduce oil consumption and satisfy energy and chemical demand. Production of biogas (mainly methane & CO2) from animal farms in Europe and discovery of shale gas (~ 90% methane) worldwide has led researchers to revisit dry reforming of methane (DRM) into syngas (CO+H2). The use of biogas as feed for chemical production not only curb the global carbon footprint, but also open up avenues for the exploration of new concepts and opportunities for catalytic and industrial developments. Despite the significant potential, DRM has not been commercialized due to catalyst instability leading high operational cost. The key challenges in the field are to increase lifetime and performance of the catalyst by preventing coke formation. Knowledge of structural/morphological changes of catalyst under reaction conditions is important for rational design. To address these issues, concepts based on combined experiment and theory are proposed. Understanding catalyst structure-activity relationship, and mechanistic insights into the DRM process will be developed through operando Raman experiments and Density Functional Theory (DFT) calculations. Raman data will provide electronic state of the catalyst, catalyst structural information, nature of carbon deposits and structure-activity relationship. While, DFT studies will give reaction energy and activation barrier, which will help in understanding the reaction pathways and mechanism of coke formation. Multiscale kinetic modeling will be executed for rationalize experimental trends and establish catalyst structure-activity relationship. The knowledge obtained from this project will not only provide an insight about the effective catalyst design but also offer an avenue to explore new concepts and opportunities for industrial catalysis development.

Keywords: biogas,syngas,operand raman spectroscopy,multiscale analysis,dft calculation
Smart Objects For Intelligent Applications (SOFIA)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Embedded Computing Systems
Action type: Collaborative project
Partnership: ARTEMIS (Art-185)
Countries involved: Finland,Spain,Italy,Spain,Italy,Netherlands,Germany,Finland,Netherlands
Call:  (ARTEMIS-2008-1, 2008)
Start date: 2009-01-01
End date: 2012-03-31
Duration (months): 39.0
Total project cost (EUR): 36288349.1
EU funding (EUR): 6060154.3
Participants: 18
Project status: CLOSED

The mission of the SOFIA project is to create a semantic interoperability platform and selected set of vertical applications to form an embedded system based smart environment. We vision smart environment application and services where all the information user wants, needs and should know from local place is easily available. A key factor in these smart environments will be a common, open way of accessing information of devices in any space. Connecting real physical world with information world enriches the user experience. Simple, local mash-up applications based are build on open data and devices. This is an Internet-like revolution in physical space. Main goal of the project is to make \"embedded information\" in the physical world available for smart services - connecting physical world with information world. Common targets are to enable and maintains cross-industry interoperability, to foster innovation while maintaining value of existing legacy and to create new user interaction and interface concepts to enable users to benefit from smart environments. In particular, a major target is multi-vendor interoperability platform as platform for new services. The project addresses three application areas which represent different kind of spaces, in terms of scale and potential applications and services. Spanning from very local personal spaces, to smart housing and further to smart city the project captures the specific aspects of smart spaces and combines the requirements for common solutions. The key outcomes of the project relate to user interaction paradigms for interacting in smart environments, the common interpretability solution between many heterogeneous devices and embedded systems, and on the application development schemes that can mobilise new developers for smart environments.

Keywords: smart spaces,ubiquitous computing,local digital services,semantic interoperability
Improving beta-cell function and identification of diagnostic biomarkers for treatment monitoring in diabetes (IMIDIA)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Germany,Switzerland,France,Sweden,Germany,France,United Kingdom,Germany,Denmark,Germany,Italy,Belgium
Call:  (IMI-JU-01-2008, 2008)
Start date: 2010-02-01
End date: 2015-09-30
Duration (months): 68.0
Total project cost (EUR): 27447009.0
EU funding (EUR): 8060760.0
Participants: 21
Project status: CLOSED

An absolute or relative loss of beta-cell mass and function underlie the development of type I and type 2 diabetes.Preventing beta-cell demise or restoring their number and function is a major therapeutic goal. However,development of novel diagnostic and prognostic tools, and of novel therapeutic modalities, is hampered by the limited knowledge of the molecular pathways that control beta-cell demise in diabetes, the production of new beta-cells from progenitors,or the replication and preserved function of mature beta-cells. Here,we propose an integrated approach to generate and exploit new cellular and animal models, and to develop novel investigative tools and biomarkers to gain new knowledge on the mechanisms of beta-cell function and demise in diabetes, to improve diabetes diagnostic and to identify novel therapeutic targets for drug development. To achieve this ambitious goal,we have established a consortium of leading European experts from universities and SMEs in the fields of beta-cell diabetes research, gene transfer technology, metabolom ics, biomedical imaging, bioinformatics and systems modeling. We propose a work plan composed of 5 scientific work packages structured to provide high levels of interaction within the network and with EFPIA partners. A management and administration work package will permit an efficient cooperation between universities, SMEs and industrial partners to ensure that the particular interests and needs of pharmaceutical industry research are addressed.
SUrrogate markers for vascular Micro- and Macrovascular hard endpoints for Innovative diabetes Tools (SUMMIT)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Germany,Sweden,Finland,Sweden,Germany,Italy,United Kingdom,United Kingdom,United Kingdom,Sweden,United Kingdom,Italy,United Kingdom,United Kingdom,Switzerland,Germany
Call:  (IMI-JU-01-2008, 2008)
Start date: 2009-11-01
End date: 2015-10-31
Duration (months): 72.0
Total project cost (EUR): 34812081.0
EU funding (EUR): 14654559.0
Participants: 26
Project status: CLOSED

Diabetes mellitus is a lifelong, incapacitating disease affecting multiple organs. Worldwide prevalence figures estimate that there will be 246 million diabetic patients in 2007 and 380 million in 2025. Presently, diabetes can neither be prevented nor cured and the disease is associated with devastating chronic complications including coronary heart disease and stroke (macrovascular disease) as well as microvascular disorders leading to damage of the small blood vessels of the kidney (nephropathy), eye(retinopathy) and peripheral nerves (neuropathy). These complications impose an immense burden on the quality of life of the patients and account for more than 10% of health care costs in Europe. Therefore, novel means to prevent these devastating diabetic complications are needed. An important mean in this undertaking would be to develop tools which would make development of novel drugs for prevention of complications more feasible. The SUMMIT consortium brings together European key leaders in the field of diabetes research; scientists with a deep insight into genetics, biomarker discovery, development of novel imaging assays for assessing progression of complications, novel animal models for chronic diabetic complications, in silico models to predict development of complications and response to novel treatments. Given the track record of this unique group of scientists, it can be anticipated that they will not only during the 6-year period discover novel surrogate markers for vascular complications in diabetes, but also validate them in large representative cohorts aiming at prevention of the devastating complications.

Keywords: summit
Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Switzerland,Netherlands,United Kingdom,United Kingdom,Italy,Italy,Denmark,Poland,Hungary,France,Germany,Sweden,Belgium,France,Denmark,Sweden,United Kingdom,Norway,Netherlands,Belgium,Netherlands,Spain,Germany,Netherlands,United States,United Kingdom,United Kingdom,Belgium
Call:  (IMI-JU-01-2008, 2008)
Start date: 2009-10-01
End date: 2015-09-30
Duration (months): 72.0
Total project cost (EUR): 26925702.0
EU funding (EUR): 9935501.0
Participants: 42
Project status: CLOSED

Rationale The inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma this bottleneck results from: a lack of useful and validated biomarkers, underperforming pre-clinical models, inadequate and incomplete sub-phenotyping, and insufficient disease understanding. Hypothesis The use of biomarker profiles comprised of various types of high-dimensional data, integrated with an innovative systems biology approach into distinct phenotype handprints, will enable significantly better prediction of therapeutic efficacy than single or even clustered biomarkers of one data type and will identify novel targets. Strategy U-BIOPRED proposes a staged-strategy: I)Generating an international consensus on diagnostic criteria for severe asthma. II)Unbiased discovery of sub-phenotypes of severe asthma in adult and paediatric patient cohorts using biomarker profiles (“fingerprints”) and systems biology to define “phenotype/handprints”. III)Validating the handprints for exacerbations, disease progression, and experimental challenges. IV)Using the handprints to improve human/animal in vivo and ex vivo models. V)Establishing the responsiveness and predictability of the handprints in gold standard and experimental therapeutic interventions. VI)Refinement of the diagnostic criteria and definition of severe asthma sub-phenotypes by incorporating the handprints, thereby enabling more focused drug development and faster delivery proof of concept for novel drugs. VII)Education, training and dissemination through a stakeholder platform and academic-industrial exchange, with potential for further growth as appropriate. Innovative approach We will use a novel systems biology approach to integrate high dimensional data from invasive, non-invasive and patient-reported outcomes. All studies will include academic and EFPIA partners as active contributors.

Keywords: u-bio
Pharmaceutical Medicine Training Programme (PHARMATRAIN)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Switzerland,Hungary,France,United Kingdom,United Kingdom,United Kingdom,Ireland,Austria,Serbia,Germany,Germany,Sweden,Sweden,Denmark,France,Italy,Spain,Belgium,Netherlands,Germany,Germany,Denmark,France,Belgium,Finland,Netherlands,Germany
Call:  (IMI-JU-01-2008, 2008)
Start date: 2009-05-01
End date: 2014-04-30
Duration (months): 60.0
Total project cost (EUR): 7631528.0
EU funding (EUR): 3510300.0
Participants: 50
Project status: CLOSED

The proposed Pharmaceutical Medicine Training Programme provides a comprehensive solution for the complex needs of integrated drug development for all professionals involved, incl. physicians, pharmaceutical scientists,biologists, biometricians, health economists, and safety and regulatory scientists from universities, regulatory agencies, large, middle-sized and small pharmaceutical enterprises, and allied companies providing contract research services, finance, clinical supplies, product manufacture and information, as well as from research ethics committees – as set out in the IMI Call Text Project # 16, p. 88-99. Eventually, this broad-based training platform programme will be tailored towards greatly enhancing the skillsetsand competencies of all key contributors to the drug development and regulatory processes using the latestscientific approaches to base the development of medicines on pathophysiology, safety and risk-awareness patient and population-based benefit as well as to make the process faster, more economical and more competitive with other parts of the world than hitherto. To address this, a pan-European comprehensive multi-modular training programme at the Master level – Master of Advanced Studies in Pharmaceutical Medicine/Drug Development Sciences (MDDS) – and other targeted programmes will be targeted for Specialists within this IMI-programme. The programme will comply with the Bologna credit and title system, and will be well-structured, self-sustaining and underpinned by a quality management system.

Keywords: pharma train